Saviela AG was established in 2008 to invest in the pharmaceutical value chain. It established a trading house for Active Pharmaceutical Ingredients and obtained Swissmedic approval in 2010. In 2014 Saviela made an equity investment in a biotechnology company in which it still participates.
Since 2010 Saviela participated in various biotechnology research projects and currently holds a portfolio of patents and trademarks. The company is privately owned and funded.